+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Xtandi), by Distribution Channel, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 80 Pages
  • October 2022
  • Region: Global
  • Grand View Research
  • ID: 4312504
Description Jump to:
The global prostate cancer therapeutics market size is expected to reach USD 21.5 billion by 2030. The market is expected to expand at a CAGR of 8.2% from 2022 to 2030. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

Prostate Cancer Therapeutics Market Report Highlights

  • By drug class, the hormonal therapy segment held the largest share and is expected to be the fastest-growing segment due to the availability and efficient mechanism of action for treating the diseased condition completely
  • Xtandi drug is expected to grow at the fastest rate over the forecast period due to the high adoption of the drug and usage of the drug for longer periods of time
  • North America dominated the market in 2021 and is anticipated to be the fastest-growing region owing to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region
  • Key market players operating in the market are focusing on developing novel products to meet the demand and provide efficient treatment options


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Prostate Cancer Therapeutics Market: Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 Prostate Cancer Therapeutics Market: Executive Summary
2.1 Market Summary
Chapter 3 Prostate Cancer Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Rise in prevalence of prostate cancer
3.3.1.2 Adoption of novel screening and diagnostic technologies
3.3.1.3 Government support for new therapies
3.3.1.4 Presence of a strong pipeline
3.3.2 Market Restraint Analysis
3.3.2.1 High cost of targeted therapies
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 User Perspective Analysis
Chapter 4 Prostate Cancer Therapeutics Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 5 Prostate Cancer Therapeutics Market: Drug Class Business Analysis
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2021 & 2030
5.3 Global Prostate Cancer Therapeutics Market, By Drug Class, 2018 To 2030
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hormonal Therapy
5.4.1.1 Hormonal Therapy Market, 2018 - 2030 (USD Million)
5.4.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
5.4.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists Market, 2018 - 2030 (USD Million)
5.4.1.1.2 Zytiga
5.4.1.1.2.1. Zytiga Market, 2018 - 2030 (USD Million)
5.4.1.1.3 Gonax
5.4.1.1.3.2 Gonax Market, 2018 - 2030 (USD Million)
5.4.1.3 Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
5.4.1.1.3. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Market, 2018 - 2030 (USD Million)
5.4.1.4 Lupron
5.4.1.1.4.1 Lupron Market, 2018 - 2030 (USD Million)
5.4.1.2.5 Zoladex
5.4.1.1.5.2 Zolodex Market, 2018 - 2030 (USD Million)
5.4.1.2.6 Eligard
5.4.1.1.6.3 Eligard Market, 2018 - 2030 (USD Million)
5.4.1.2.7 Decapeptyl
5.4.1.1.7.1 Decapeptyl Market, 2018 - 2030 (USD Million)
5.4.1.2.8 Vantas
5.4.1.1.8.1 Vantas Market, 2018 - 2030 (USD Million)
5.4.1.2.9 Others
5.4.1.1.9.1 Others Market, 2018 - 2030 (USD Million)
5.4.1.3. Anti-Androgen
5.4.1.3.1. Anti-Androgen Market, 2018 - 2030 (USD Million)
5.4.1.3.2 Xtandi
5.4.1.1.2.1. Xtandi Market, 2018 - 2030 (USD Million)
5.4.1.3.3 Casodex
5.4.1.1.3.1. Casodex Market, 2018 - 2030 (USD Million)
5.4.2. Chemotherapy
5.4.2.1 Chemotherapy Market, 2018 - 2030 (USD Million)
5.4.2.1. Taxotere
5.4.2.1.1. Taxotere Market, 2018 - 2030 (USD Million)
5.4.2.2. Jevtana
5.4.2.1.2 Jevtana Market, 2018 - 2030 (USD Million)
5.4.3. Immunotherapy
5.4.3.1 Immunotherapy Market, 2018 - 2030 (USD Million)
5.4.3.2. Provenge
5.4.3.2.1. Provenge Market, 2018 - 2030 (USD Million)
5.4.4. Targeted Therapy
5.4.4.1 Targeted Therapy Market, 2018 - 2030 (USD Million)
5.4.4.2. Xofigo
5.4.4.2.1 Xofigo Market, 2018 - 2030 (USD Million)
5.4.5 Others
5.4.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Prostate Cancer Therapeutics Market: Distribution Channel Business Analysis
6.1 Definition and Scope
6.2 Distribution Channel Market Share Analysis, 2021 & 2030
6.3 Global Prostate Cancer Therapeutics Market, By Distribution Channel, 2018 To 2030
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospital Pharmacies
6.4.1.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.4.2. Drug Stores & Retail Pharmacies
6.4.2.1 Drug Stores & Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.4.3. Online Pharmacies
6.4.3.1 Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 7 Prostate Cancer Therapeutics Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8 Europe
7.8.1 Europe Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 France
7.8.4.1 France Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia Pacific Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.9.3 China
7.9.3.1 China Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.9.4 India
7.9.4.1 India Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.4 Australia
7.8.4.1 Australia Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.5 South Korea
7.8.5.1 South Korea Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 Argentina
7.8.3.1 Argentina Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.11 MEA
7.11.1 MEA Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.2 Saudi Arabia
7.8.2.1 Saudi Arabia Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
7.8.3 UAE
7.8.3.1 UAE Prostate Cancer Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 8 Prostate Cancer Therapeutics Market: Company Profiling
8.1 Company Profiles
8.1.1. Johnson & Johnson Services, Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic Initiatives
8.1.2. Astellas Pharma Inc.
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic Initiatives
8.1.3. Eli Lilly and Company
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic Initiatives
8.1.4. Sanofi
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic Initiatives
8.1.5. Ipsen Pharma
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic Initiatives
8.1.6. Bayer AG
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic Initiatives
8.1.7. AstraZeneca
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic Initiatives
8.1.8. Valeant Pharmaceuticals International, Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic Initiatives
8.1.9. Merck & Co., Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic Initiatives
8.1.10. Pfizer Inc.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Prostate Cancer Therapeutics Market, By Region, 2018-2030 (USD Million)
Table 5 Global Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 6 Global Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 7 North America Prostate Cancer Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 8 North America Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 9 North America Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 10 U.S. Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 11 U.S. Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 12 Canada Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 13 Canada Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 14 Europe Prostate Cancer Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 15 Europe Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 16 Europe Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 17 U.K. Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 18 U.K. Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 19 Germany Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 20 Germany Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 21 France Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 22 France Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 23 Italy Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 24 Italy Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 25 Spain Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 26 Spain Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 27 Asia Pacific Prostate Cancer Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 28 Asia Pacific Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 29 Asia Pacific Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 30 China Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 31 China Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 32 Japan Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 33 Japan Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 34 India Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 35 India Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 36 Australia Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 37 Australia Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 38 South Korea Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 39 South Korea Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 40 Latin America Prostate Cancer Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 41 Latin America Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 42 Latin America Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 43 Brazil Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 44 Brazil Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 45 Mexico Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 46 Mexico Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 47 Argentina Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 48 Argentina Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 49 MEA Prostate Cancer Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 50 MEA Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 51 MEA Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 52 South Africa Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 53 South Africa Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 54 Saudi Arabia Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 55 Saudi Arabia Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 56 UAE Prostate Cancer Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 57 UAE Prostate Cancer Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Prostate Cancer Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration Vs Growth Prospect Mapping
Fig. 15 Prostate Cancer Therapeutics Market: Drug Class Movement Analysis
Fig. 16 Hormonal Therapy Market, 2018-2030 (USD Million)
Fig. 17 Zytiga Market, 2018-2030 (USD Million)
Fig. 18 Gonax Market, 2018-2030 (USD Million)
Fig. 19 Lupron Market, 2018-2030 (USD Million)
Fig. 20 Zoladex Market, 2018-2030 (USD Million)
Fig. 21 Eligard Market, 2018-2030 (USD Million)
Fig. 22 Decapeptyl Market, 2018-2030 (USD Million)
Fig. 23 Vantas Market, 2018-2030 (USD Million)
Fig. 24 Xtandi Market, 2018-2030 (USD Million)
Fig. 25 Casodex Market, 2018-2030 (USD Million)
Fig. 26 Chemotherapy Market, 2018-2030 (USD Million)
Fig. 27 Taxotere Market, 2018-2030 (USD Million)
Fig. 28 Jevtana Market, 2018-2030 (USD Million)
Fig. 29 Immunotherapy Market, 2018-2030 (USD Million)
Fig. 30 Provenge Market, 2018-2030 (USD Million)
Fig. 31 Targeted Therapy Market, 2018-2030 (USD Million)
Fig. 32 XoFigo Market, 2018-2030 (USD Million)
Fig. 33 Others Market, 2018-2030 (USD Million)
Fig. 34 Prostate Cancer Therapeutics Market: Distribution Channel Movement Analysis
Fig. 35 Hospital Pharmacies Market, 2018-2030 (USD Million)
Fig. 36 Drugs Stores and Retail Pharmacies Market, 2018-2030 (USD Million)
Fig. 37 Online Pharmacies Market, 2018-2030 (USD Million)
Fig. 38 Regional Marketplace: Key Takeaways
Fig. 39 Regional Outlook, 2018 & 2030
Fig. 40 Regional Market Dashboard
Fig. 41 Regional Market Place: Key Takeaways
Fig. 42 North America, SWOT Analysis
Fig. 43 Europe, SWOT Analysis
Fig. 44 Asia Pacific, SWOT Analysis
Fig. 45 Latin America, SWOT Analysis
Fig. 46 MEA, SWOT Analysis
Fig. 47 North America
Fig. 48 North America Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 49 U.S.
Fig. 50 U.S. Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 51 Canada
Fig. 52 Canada Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 53 Europe
Fig. 54 Europe Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 55 U.K.
Fig. 56 U.K. Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 57 Germany
Fig. 58 Germany Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 59 France
Fig. 60 France Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 61 Italy
Fig. 62 Italy Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 63 Spain
Fig. 64 Spain Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 65 Asia Pacific
Fig. 66 Asia Pacific Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 67 Japan
Fig. 68 Japan Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 69 China
Fig. 70 China Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 71 India
Fig. 72 India Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 73 Australia
Fig. 74 Australia Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 75 South Korea
Fig. 76 South Korea Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 77 Latin America
Fig. 78 Latin America Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 79 Brazil
Fig. 80 Brazil Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 81 Mexico
Fig. 82 Mexico Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 83 Argentina
Fig. 84 Argentina Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 85 MEA
Fig. 86 MEA Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 87 South Africa
Fig. 88 South Africa Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 89 Saudi Arabia
Fig. 90 Saudi Arabia Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 91 UAE
Fig. 92 UAE Market Estimates And Forecast, 2018-2030 (USD Million)
Fig. 93 Strategy Mapping

Companies Mentioned

  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Sanofi
  • Ipsen Pharma
  • Bayer AG
  • Astrazeneca
  • Valeant Pharmaceuticals International, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages80
PublishedOctober 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11301.3 Million
Forecasted Market Value ( USD ) by 2030 $ 21500 Million
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Prostate Cancer Therapeutics Market by Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Distribution Channel (Drug Stores & Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies) - Forecast 2024-2030 - Product Image

Global Prostate Cancer Therapeutics Market by Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Distribution Channel (Drug Stores & Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies) - Forecast 2024-2030

  • Report
  • 196 Pages
  • Global
From
Prostate Cancer Therapeutics: Global Strategic Business Report - Product Image

Prostate Cancer Therapeutics: Global Strategic Business Report

  • Report
  • 212 Pages
  • Global
From
Global Prostate Cancer Therapeutics Market - Product Image

Global Prostate Cancer Therapeutics Market

  • Report
  • 200 Pages
  • Global
From
Global Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Preliminary Tests, Confirmatory Tests), Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), End Use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Preliminary Tests, Confirmatory Tests), Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), End Use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 152 Pages
  • Global
From
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report by Type (SPECT, PET), PET Product (F-18, SR-82/RB-82), and Segment Forecasts, 2023-2030 - Product Image

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report by Type (SPECT, PET), PET Product (F-18, SR-82/RB-82), and Segment Forecasts, 2023-2030

  • Report
  • 80 Pages
  • United States
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.